Davita Inc vs First Solar, Inc. — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while First Solar, Inc. trades at $177.82 (market cap $19.22B). The key difference: First Solar, Inc. is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and First Solar, Inc. for 76 Days on average.
| DVA | FSLR | |
|---|---|---|
Market Cap | $11.29B | $19.22B |
Volume | 582,204 | 2,067,793 |
Sector | Health | Energy |
52-Week High | $240.96 | $318.30 |
52-Week Low | $103.87 | $172.11 |
Typical Hold Time | 114 Days | 76 Days |
Enterprise Value | $24.01B | $17.69B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
First Solar (FSLR) trades at $177.82, down 1.28% on the day, amid a bearish technical signal and recent sector-wide pressures. The stock shows strong fundamentals with a P/E of 11.03, net income margin of 32.47%, and robust cash flow from operations of $2.06B in 2025. Recent news includes a patent infringement lawsuit filed on October 1, 2026, which briefly lifted the stock, while high put option volume on October 3, 2026, indicates investor caution.
FSLR presents a mixed outlook: solid profitability and analyst consensus support a 'Moderate Buy' with a $267.59 price target, but technical weakness and solar sector headwinds from high borrowing costs pose near-term risks. The stock's 44.9% decline from its all-time high highlights volatility, yet earnings beats in Q1 and Q2 2026 underscore operational strength.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →